Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma.
We have studied the effect of RG 12525, an oral leukotriene D4 (LTD4) antagonist, on LTD4-induced bronchoconstriction in eight male subjects with mild asthma (baseline FEV1 greater than 80% predicted) in a double-blind, placebo-controlled fashion. RG 12525 800 mg displaced the dose-response curve for LTD4 to the right. The mean (95% confidence intervals) difference in log PC20FEV1 following RG 12525 and placebo was 2.88 (1.61, 4.17) doubling doses of LTD4 (P less than 0.01), a 7.5 fold difference. We conclude that RG 12525 when administered orally is an effective LTD4 antagonist in subjects with mild asthma.
Wahedna
I
I
Respiratory Medicine Unit, City Hospital, Nottingham.
Wisniewski
A S
AS
Tattersfield
A E
AE
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000503:physiopathology*; D016084:Bronchoconstriction / Q000187:drug effects*; D004311:Double-Blind Method; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000494:pharmacology*; D013189:SRS-A / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology*
D011804:Quinolines; D013189:SRS-A; D013777:Tetrazoles; C059101:RG 12525